Correspondence 0001104659-23-116029 from BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893) (BTAI)
BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893)
Date: Nov. 9, 2023 · CIK: 0001720893 · Accession: 0001104659-23-116029
AI Filing Summary & Sentiment
File numbers found in text: 333-275261
Letter
BioXcel Therapeutics, Inc.
555 Long Wharf Drive
New Haven, CT 06511
November 9, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Joshua Gorsky
Re: BioXcel Therapeutics, Inc.
Registration Statement on Form S-3 Filed November 2, 2023
File No. 333-275261
To the addressees set forth above:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, BioXcel Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-275261) be accelerated by the Securities and Exchange Commission to 9:00 a.m. Washington D.C. time on November 14, 2023 or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to Keith L. Halverstam of Latham & Watkins LLP at (212) 906-1761 or N. Danny Shulman at (212) 906-4510 and that such effectiveness also be confirmed in writing.
Sincerely,
BioXcel Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
BioXcel Therapeutics, Inc.
555 Long Wharf Drive
New Haven, CT 06511
November 9, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Joshua Gorsky
Re:
BioXcel Therapeutics, Inc.
Registration Statement on Form S-3 Filed November 2, 2023
File No. 333-275261
To the addressees set forth above:
Pursuant to Rule 461(a) under the Securities Act
of 1933, as amended, BioXcel Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective
date of the Company’s Registration Statement on Form S-3 (File No. 333-275261) be accelerated by the Securities and Exchange Commission
to 9:00 a.m. Washington D.C. time on November 14, 2023 or as soon as practicable thereafter.
The Company requests that we be notified of such
effectiveness by a telephone call to Keith L. Halverstam of Latham & Watkins LLP at (212) 906-1761 or N. Danny Shulman at (212) 906-4510
and that such effectiveness also be confirmed in writing.
Sincerely,
BioXcel Therapeutics, Inc.
By:
/s/ Richard Steinhart
Richard Steinhart
Chief Financial Officer
cc:
Keith L. Halverstam, Latham & Watkins LLP
N. Danny Shulman, Latham & Watkins LLP